U.S. Markets close in 2 hrs 28 mins

4 Stocks To Watch As Healthcare Technology Industry Is Expecting Rapid Growth Through 2025

CORAL GABLES, FL / ACCESSWIRE / November 13, 2018 / The U.S. patient engagement solutions market size is anticipated to reach $12.3 billion by 2025, expanding at a CAGR of 19.5% over the forecast period according to reports from Research And Markets*. The report states that, ''Increasing awareness regarding patient engagement solutions among government organizations such as the Agency of Healthcare Research and Quality and the Office of National Coordinator for Health Information Technology (ONC) is expected to fuel market growth.''

With the volatility in today's market, many investors have turned to biotechnology and healthcare stocks as a safe haven from the broader market activity. Furthermore, the new age of technology and aging population unable to frequently visit a physical doctor's office has created a larger demand for technology intervention within the healthcare industry. Increasing use of mobile health is considered to be the key driver for the U.S. Patient engagement solutions market. Rising awareness and need for monitoring personal health have led to increased usage of mobile health applications across the globe. The market has been segmented into delivery type, component, end-use, application, and therapeutic area.

New trends like these have brought more attention to companies like Premier Health Group, Inc. (PHGRF) (PHGI), Viking Therapeutics (VKTX), Teladoc Health (TDOC) and Matinas BioPharma Holdings, Inc. (NYSE American: MTNB).

Premier Health Group, Inc. (PHGRF) (PHGI) announced this month that as a part of its expansion plans it will be entering the Pharmacy market ''via acquisition and/or launching a new Canada based pharmacy in H1-2019.'' With Premier's acquisition of HealthVue Medical Clinics in August, this could be the next phase of growth for the company. Premier Health Group, Inc. (PHGRF) (PHGI) said that it expects to provide additional updates on acquisitions in Q4-18 and Q1-19 so this could be one of the near term events to consider when looking at Premier Health Group, Inc. (PHGRF) (PHGI).

The Canadian retail pharmacy market is estimated to be $44 billion (Source:IBISWorld). It is expected the industry sector will continue to allow for favorable economics for pharmacy operators as baby boomer's demand increases for prescriptions and operators expand scope of practice to include preventative services.

Furthermore, the company has begun building its technology framework to continue it expansion of its HealthVue subsidiary. Premier Health Group, Inc. (PHGRF) (PHGI) announced that it has selected Reliq Health Technologies Inc. as its exclusive technology partner. Reliq will be providing Premier's subsidiary, HealthVue, primary care clinics with a HealthVue-branded telemedicine, remote monitoring & AI solution for its clinical staff and more than 100,000 active patients.

Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry. The company has recently seen market activity that is higher than average and could be attributed to the company's most recent announcements.

For More Information On Premier Health Group, Click Here

Viking Therapeutics (VKTX) was on the top trending healthcare stocks to watch this morning. The company is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Today Viking announced the presentation of results from the company's 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C). As previously reported, the study successfully achieved both its primary and secondary endpoints, and demonstrated an encouraging safety and tolerability profile.

Newly presented data provide further detail on the trial endpoints, highlighting the changes to LDL-C, atherogenic proteins, and other liver parameters. The results were presented Monday, November 12 as part of the Oral Late-Breaker session of The Liver Meeting® 2018, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), held November 9-13 in San Francisco, CA.

"The fact that two-thirds of patients treated with VK2809 achieved at least a 50% reduction in liver fat content is striking, particularly in light of the relatively short duration of treatment evaluated in this trial. While our research suggests that reducing liver fat by at least 30% increases the likelihood of triggering a potential histologic response in non-alcoholic steatohepatitis (NASH) patients, we would expect that patients who have their liver fat content reduced by more than half may even have a higher likelihood of improvement in liver histology when assessed in a future biopsy-based trial," stated Rohit Loomba, M.D., MHSc, Director, NAFLD Research Center, and Professor of Medicine, University of California at San Diego.

For More Information On Viking, Click Here

Teladoc Health (TDOC), similar to Premier Health mentioned above, is targeting the virtual care healthcare industry. On Monday the company unveiled a partnership with Jefferson (Philadelphia University and Thomas Jefferson University) to create the industry's first academic fellowship program in the field of telehealth. Having launched for the fall 2018 semester at Sidney Kimmel Medical College at Thomas Jefferson University, the fellowship formalizes a training and education program to advance the field of telehealth by creating a specialized curriculum for those pursuing careers in telehealth.

According to Teladoc, the educational partnership will support the fellows at Jefferson on a path to telehealth management similar in nature to public health training. There are two distinct components of the program; one led and held onsite at Jefferson Health, and the other designed and delivered by Teladoc Health.

''As virtual care has proven to be a cornerstone of the healthcare ecosystem, Teladoc Health is proud to be partnering with Jefferson to prepare the next generation of telehealth leaders for success,'' said Alan Roga, MD, president, Hospital & Health Systems, Teladoc Health. ''With a shared commitment to deliver both a better patient experience and the highest quality care, together Jefferson Health and Teladoc Health are leading the industry forward and setting the bar for others to follow.''

For More Information On Teladoc, Click Here

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) is a clinical-stage biopharmaceutical company. This week the company announced its financial results for the third quarter ended September 30, 2018 and provided a corporate update.

Jerome D. Jabbour, Chief Executive Officer of Matinas. ''In witnessing the enthusiasm and potential surrounding our differentiated LNC platform delivery technology, coupled with recent third-party landmark data announcements demonstrating that certain omega-3 fatty acids can have a significant impact on overall cardiovascular health, we find ourselves in the enviable position of having two potential best-in-class assets. As the only drug currently in development with head-to-head data demonstrating statistical superiority to Vascepa® on a variety of lipid measures, highlighted by an approximately six-fold higher AUC and Cmax and higher blood levels of EPA, MAT9001 is uniquely positioned to aggressively move forward in development with the assistance of a world class team of advisors. While recently announced data in this space is very impressive, we believe there are exciting opportunities to create potential differentiation and be very thoughtful with trial design and execution. Our goal with this clinical development program is to establish MAT9001 as a potential best-in-class therapy for the benefit of patients in this projected multi-billion dollar emerging prescription-only omega-3 class.''

Shares of Matinas pulled back at the end of the day on Monday but have since begun to rebound during premarket trading on Tuesday morning.

For More Information On Matinas, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

*ResearchAndMarkets Report: https://www.researchandmarkets.com/research/xmkv79/united_states_12?w=5

Contact Information:

news@stockprice.com

SOURCE: StockPrice.com